Developer docs
API playgroundTry for free, no card

Search company profiles

HollandPTC

Full company profile

uuid000rev4

Namestring
HollandPTC
Legal namestring
HollandPTC
Websiteurl
hollandptc.nl
Company typeenum
Private
Founded yearint
2018
Descriptiontext

HollandPTC (Holland Protonen Therapie Centrum) is an independent outpatient proton therapy center located in Delft, Netherlands, founded in 2018 by a consortium of three Dutch institutions: Erasmus MC (Rotterdam), LUMC (Leiden), and TU Delft. The center operates under a WBMV (Wet Bijzondere Medische Verrichtingen) license granted by the Dutch Ministry of VWS in December 2013, with a statutory annual treatment capacity of 600 patients. Its core clinical offering is proton therapy — using accelerated protons rather than photons to exploit the Bragg peak effect, depositing maximum radiation dose in the tumor while sparing surrounding healthy tissue. The facility houses three treatment rooms (De Luit, De Citer, and De Parel, the last specialized for ocular melanoma), and is the only center in the Netherlands authorized to treat ocular tumors with protons; pediatric cases are referred to UMCG in Groningen.

The technology stack includes pencil-beam scanning, image-guided adaptive proton therapy integrating CT/MRI/PET-CT, and a research pipeline covering FLASH proton therapy (≥40 Gy/s) and real-time in-vivo dosimetry using sub-100 picosecond PET detectors. Beyond clinical care, HollandPTC runs a substantial research program across clinical studies, high-precision technology, health economics, FLASH, and combination therapies, with technology and research partnerships with Varian Medical Systems, Siemens Healthineers, Philips, RaySearch Laboratories, and academic networks including EPTN, DUPROTON, and Medical Delta.

Commercially, HollandPTC generates revenue from proton therapy treatment services reimbursed by Dutch mandatory health insurance. Standard indications (ocular melanoma, skull-base chordomas/chondrosarcomas, seminoma, pediatric cases via Groningen) are automatically reimbursed; model-based indications (breast, head/neck, lung, lymphoma, esophageal) require a national plan comparison demonstrating superior risk profiles. International and self-pay patients are billed at passerentarieven set by the Nederlandse Zorgautoriteit. Go-to-market is referral-based: Dutch hospital radiotherapist-oncologists assess eligibility and refer patients through the standardized TWIIN portal, with additional commercial access offered to research users via the Beamtime Call mechanism.

Short descriptiontext

HollandPTC is a Dutch outpatient proton therapy center in Delft, founded by Erasmus MC, LUMC, and TU Delft, delivering precision proton radiation for cancer patients under a WBMV-licensed 600-patient annual capacity while conducting clinical and physics research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDelft, Netherlands
HQ citystring
Delft
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
proton therapy, radiation oncology, cancer treatment center, ocular melanoma treatment, particle therapy
Industry3 codes
PRIMARYHLAKAFAC
Radiation Oncology
SECONDARYHLAIAGAI
Nuclear Medicine Clinical Services & Therapy Centers
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAHABAH
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code2 codes
  • Diagnostic Imaging Centers621512
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Services-Health Services8000
Product category
Proton Therapy / Radiation Oncology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Proton therapy treatment services
TypeSubscription Recurring
Description

HollandPTC provides proton therapy treatment services reimbursed by Dutch health insurers. For standard indications, proton therapy is automatically covered by insurance. For model-based indications, a treatment plan comparison determines eligibility and coverage. International patients without Dutch insurance pay passer tariffs. Treatment costs are covered by mandatory Dutch health insurance, with patients responsible for their deductible (eigen risico).

hollandptc.nl
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Infrastructure, Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details3 tiers
1Standard indications - automatically reimbursed proton therapy
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Health insurers automatically reimburse proton therapy for standard indications including: children with malignant tumors (treated in Groningen), ocular melanoma, chordomas/chondrosarcomas of the skull base and spine, and seminoma. Patients pay their standard deductible.

hollandptc.nl
2Model-based indications - plan comparison required
ModelSubscriptionBilling cadenceMulti-year contract
Notes

For other cancer types (breast cancer, brain tumors, head and neck tumors, lung cancer, lymphoma, esophageal cancer), a plan comparison is made between photon and proton therapy. If proton therapy shows significantly lower side effect risk, it is reimbursed. National agreements specify which tumors require plan comparison and the threshold for benefit.

hollandptc.nl
3International/self-pay patients
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Foreign insured patients require payment guarantee from their insurer. Patients with conscientious objections to insurance receive 25% deposit upfront, remaining 75% after final treatment. Passantentarieven (passer rates) available from Nederlandse Zorgautoriteit.

hollandptc.nl
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

HollandPTC is an independent outpatient proton therapy center that delivers precise radiation treatment to cancer patients using accelerated proton beams, exploiting the Bragg peak to concentrate dose in tumors while sparing surrounding healthy tissue. In addition to clinical care, the center conducts scientific research in biology, physics and technology, and clinical studies, and runs education programs for radiation oncologists, medical physicists, and radiotherapy technologists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Health insurers reimburse treatment for standard indications automatically
+3 more records
Product overview1 text field

HollandPTC (Holland Protonen Therapie Centrum) is a specialized proton therapy center founded by Erasmus MC, LUMC, and TU Delft. The organization operates three core functions: patient care (Protonentherapie), scientific research (Wetenschappelijk Onderzoek), and education (Onderwijs). Patient care includes precise proton radiation treatment for various cancers using three treatment rooms named Luit, Citer, and Parel. The research program covers five themes: Clinical Studies, High-Precision Proton Therapy, Health Economics, Flash Proton Therapy, and Combined Treatment Research. HollandPTC also operates a specialized Eye Treatment Line for ocular melanoma, the only such center in the Netherlands. The organization develops custom in-house software and hardware for treatment planning and delivery, though these are internal tools rather than commercial products.

Product and service11 records
1Proton Therapy (Protonentherapie)
CategoryClinical proton therapy treatment
Description

Precise radiation therapy using accelerated protons instead of photons to treat cancer, enabling targeted tumor irradiation with reduced damage to surrounding healthy tissue and lower side effects. Provided to cancer patients referred by Dutch radiotherapist-oncologists.

2Patient Care (Patiëntenzorg)
CategoryClinical patient services
Description

Comprehensive patient care service including treatment planning, radiation delivery, and follow-up monitoring for proton therapy patients treated at HollandPTC.

3Scientific Research (Wetenschappelijk Onderzoek)
CategoryResearch and development
Description

Cross-disciplinary research program focused on enhancing the added value of proton therapy through biology, physics & technology, and clinical studies. Includes research projects, researcher teams, and publication output.

4Education and Knowledge Sharing (Onderwijs en Kennisdeling)
CategoryEducation and training
Description

Educational programs and knowledge sharing for radiation oncologists, clinical physicists, radiotherapy technologists, and technical personnel. Includes Boerhaave Nascholing e-learning and access to clinical and pre-clinical facilities.

5HollandPTC Eye Treatment Line (Ooglijn) for Ocular Melanoma
CategorySpecialized clinical service
Description

Specialized proton therapy treatment line for ocular melanoma using advanced techniques including clipless MR-eye guided planning, delivered in the dedicated De Parel treatment room. Provided to ocular melanoma patients in the Netherlands.

6Plan Comparison (Planvergelijking)
CategoryClinical decision support service
Description

Clinical service comparing photon radiation treatment plans with proton therapy plans for individual patients with model-based indications to determine whether proton therapy offers better outcomes with fewer side effects, including ΔNTCP-based eligibility assessment.

7Clinical Studies at HollandPTC
CategoryResearch service
Description

Clinical research evaluating accepted and new clinical indications and testing new treatment strategies including hypofractionation, adaptive proton therapy, and combination therapy.

8High-Precision Proton Therapy Research
CategoryResearch service
Description

Research program focused on enhancing proton therapy through development and implementation of new technology and methodologies including advanced pre-treatment imaging, online adaptation, motion mitigation, AI use, and automated and probabilistic treatment planning.

9Health Economics Research
CategoryResearch service
Description

Research program assessing the health-economic benefits of proton therapy to determine its value, cost-effectiveness, and identify opportunities to maximize effectiveness and efficiency, led through collaboration with Erasmus University Rotterdam.

10FLASH Proton Therapy Research
CategoryResearch service
Description

Research program dedicated to understanding, developing, and clinically testing ultra-high dose rate proton therapy (≥40 Gy/s) with specific focus on the FLASH effect.

11Combined Treatment Research
CategoryResearch service
Description

Research program investigating proton therapy interaction with other treatments such as immunotherapy, hyperthermia, and targeted drugs to maximize treatment effectiveness in clinical practice.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Founding partner and major clinical collaborator. Erasmus MC radiotherapist-oncologists supervise treatments and conduct joint research. Prof. dr. Mischa Hoogeman serves as Principal Investigator. The partnership provides clinical expertise in radiotherapy and oncology, with joint research programs in proton therapy optimization and clinical outcomes.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Founding partner and clinical collaborator. LUMC radiotherapist-oncologists including Prof. dr. Coen Rasch supervise treatments. LUMC handles most ocular melanoma cases in the Netherlands (over 90%) and refers appropriate patients for proton therapy. Joint research in proton therapy for chordomas, vestibular schwannomas, and ocular melanoma.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Founding partner providing technical/physics expertise. TU Delft hosts HollandPTC on its campus. Joint research in proton therapy physics, imaging technology, treatment planning optimization, and AI applications. Prof. dr. Roland Kanaar and Prof. dr. Mischa Hoogeman (also Erasmus MC) lead research programs.

Strategic tierMajorTypeTechnology or Integration
Description

Equipment and technology partner providing proton therapy systems and treatment planning software. Multiple joint research projects funded including Proton-DDR (2019), vestibular schwannoma research (2018), real-time dosimetry (2020), and FLASH therapy development (2020). Also provides access for commercial users to HollandPTC facilities.

Strategic tierMajorTypeTechnology or Integration
Description

Medical imaging technology partner providing CT and other imaging systems used in treatment planning and image guidance for proton therapy.

Strategic tierMajorTypeTechnology or Integration
Description

Medical technology partner providing imaging and healthcare technology solutions supporting treatment planning and patient care operations.

Strategic tierMajorTypeTechnology or Integration
Description

Treatment planning software partner. Joint research project 'Probabilistic optimization and planning' funded by RaySearch Laboratories developing methods for probabilistic optimization in proton therapy treatment planning.

8European Proton Therapy Network (EPTN)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

European network of proton therapy centers collaborating on best practices, guidelines, and harmonization of proton therapy treatment planning and delivery across Europe.

hollandptc.nl
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Network of life sciences, health and technology partners in the Delft-Leiden-Rotterdam region. Supports Health Technology Assessment (HTA) research and cross-institutional collaboration. Prof. dr. Coen Rasch holds Medical Delta professorship linking LUMC and TU Delft.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Applied sciences university collaborating on radiation therapy technologist (RTT) training and education. Joint project 'Towards a sustainable RTT network' funded by European Union Erasmus+ program (2023) to harmonize proton therapy planning and delivery practices across Europe.

11National DUPROTON research network
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dutch national research network for proton therapy collaboration among proton therapy centers in the Netherlands.

hollandptc.nl
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration through Erasmus School of Health Policy and Management on health economics research. Dr. Hedwig Blommestein leads HTA value proposition research. PhD students from EUR conduct cost-effectiveness and health technology assessment studies.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Treatment planning software vendor and HollandPTC R&D partner. Comparable as the technology ecosystem participant whose RayStation platform is used in HollandPTC's plan-comparison workflow and whose probabilistic optimization research directly shapes the center's clinical capability.

2IBA (Ion Beam Applications)
TypeBroad incumbent
Description

Global leader in proton therapy equipment manufacturing and a broad incumbent in particle therapy. Comparable as the dominant infrastructure provider in the same clinical modality that HollandPTC operates, including competing ProteusONE/ProteusPLUS systems installed at peer centers worldwide.

TypeRegional player
Description

UK NHS proton therapy center in Manchester treating pediatric and adult cases. Comparable as a publicly funded, hospital-integrated proton therapy center operating a similar clinical-research-education model, but in a different national reimbursement system (NHS) than HollandPTC's Dutch insurer model.

TypeBroad incumbent
Description

HollandPTC's primary equipment and treatment-planning partner (ProBeam proton system). Comparable as the major radiotherapy incumbent whose installed base of photon and proton systems at other centers competes for the same oncology referral base and whose technology roadmap directly affects HollandPTC's clinical capabilities.

5UMCG Protonentherapiecentrum
TypeDirect peer
Description

Proton therapy center at the University Medical Center Groningen, the other major Dutch proton facility. Directly comparable: same country, same WBMV-regulated indication framework, treats pediatric patients that HollandPTC does not, and competes for the same Dutch patient pool and referring physicians.

6Provision CARES Proton Therapy Center (Nashville)
TypeEmerging player
Description

US proton therapy center using Mevion compact systems. Comparable as a smaller-scale, single- or multi-room proton therapy operator with similar capital intensity and capacity dynamics, though operating under a US payer mix rather than Dutch mandatory insurance.

TypeEmerging player
Description

Compact single-room proton therapy system manufacturer targeting smaller hospitals. Comparable as an emerging alternative technology platform whose success in reducing proton therapy capex could shift the competitive landscape for small-scale centers like HollandPTC.

TypeEmerging player
Description

Swiss research-and-treatment proton therapy center, historically the pioneer of pencil-beam scanning. Comparable as a research-driven proton therapy operation combining patient care with technology development (Gantry 2, Gantry 3) in a similar combined clinical-research model to HollandPTC.

9Maastro Proton Therapy
TypeDirect peer
Description

Proton therapy center at Maastro Clinic in Maastricht, the third Dutch proton facility. Directly comparable as a domestic competitor operating under the same WBMV license framework, treating overlapping model-based indications, and serving the same national referral network.

TypeBroad incumbent
Description

Global proton therapy system manufacturer and operator (formerly Mitsubishi Electric). Comparable as a broad incumbent providing competing synchrotron-based proton systems installed at multiple academic medical centers, including European sites that compete for the same European patient and research demand.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HollandPTC

Proton Therapy / Radiation Oncologyhollandptc.nl

HollandPTC is a Dutch outpatient proton therapy center in Delft, founded by Erasmus MC, LUMC, and TU Delft, delivering precision proton radiation for cancer patients under a WBMV-licensed 600-patient annual capacity while conducting clinical and physics research.

What HollandPTC does

HollandPTC (Holland Protonen Therapie Centrum) is an independent outpatient proton therapy center located in Delft, Netherlands, founded in 2018 by a consortium of three Dutch institutions: Erasmus MC (Rotterdam), LUMC (Leiden), and TU Delft. The center operates under a WBMV (Wet Bijzondere Medische Verrichtingen) license granted by the Dutch Ministry of VWS in December 2013, with a statutory annual treatment capacity of 600 patients. Its core clinical offering is proton therapy — using accelerated protons rather than photons to exploit the Bragg peak effect, depositing maximum radiation dose in the tumor while sparing surrounding healthy tissue. The facility houses three treatment rooms (De Luit, De Citer, and De Parel, the last specialized for ocular melanoma), and is the only center in the Netherlands authorized to treat ocular tumors with protons; pediatric cases are referred to UMCG in Groningen.

The technology stack includes pencil-beam scanning, image-guided adaptive proton therapy integrating CT/MRI/PET-CT, and a research pipeline covering FLASH proton therapy (≥40 Gy/s) and real-time in-vivo dosimetry using sub-100 picosecond PET detectors. Beyond clinical care, HollandPTC runs a substantial research program across clinical studies, high-precision technology, health economics, FLASH, and combination therapies, with technology and research partnerships with Varian Medical Systems, Siemens Healthineers, Philips, RaySearch Laboratories, and academic networks including EPTN, DUPROTON, and Medical Delta.

Commercially, HollandPTC generates revenue from proton therapy treatment services reimbursed by Dutch mandatory health insurance. Standard indications (ocular melanoma, skull-base chordomas/chondrosarcomas, seminoma, pediatric cases via Groningen) are automatically reimbursed; model-based indications (breast, head/neck, lung, lymphoma, esophageal) require a national plan comparison demonstrating superior risk profiles. International and self-pay patients are billed at passerentarieven set by the Nederlandse Zorgautoriteit. Go-to-market is referral-based: Dutch hospital radiotherapist-oncologists assess eligibility and refer patients through the standardized TWIIN portal, with additional commercial access offered to research users via the Beamtime Call mechanism.

HollandPTC firmographics

Firmographics
Name
HollandPTC
Legal name
HollandPTC
Website
https://hollandptc.nl
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
HollandPTC is a Dutch outpatient proton therapy center in Delft, founded by Erasmus MC, LUMC, and TU Delft, delivering precision proton radiation for cancer patients under a WBMV-licensed 600-patient annual capacity while conducting clinical and physics research.
Ownership category
akta.pro rank

HollandPTC industry classification

Industry
Product category
Proton Therapy / Radiation Oncology
NAICS
Diagnostic Imaging Centers (621512), Scientific Research and Development Services (5417)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAKAFAC
Radiation Oncology
SECONDARYHLAIAGAI
Nuclear Medicine Clinical Services & Therapy Centers
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAHABAH
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Proton therapy
  • Radiation oncology
  • Cancer treatment center
  • Ocular melanoma treatment
  • Particle therapy

Where HollandPTC is headquartered

Location

Headquarters

HQ city
Delft
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

HollandPTC business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Infrastructure, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Proton therapy treatment services: HollandPTC provides proton therapy treatment services reimbursed by Dutch health insurers. For standard indications, proton therapy is automatically covered by insurance. For model-based indications, a treatment plan comparison determines eligibility and coverage. International patients without Dutch insurance pay passer tariffs. Treatment costs are covered by mandatory Dutch health insurance, with patients responsible for their deductible (eigen risico).

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractStandard indications - automatically reimbursed proton therapy
SubscriptionMulti-year contractModel-based indications - plan comparison required
Usage-basedPay-as-you-goInternational/self-pay patients

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

HollandPTC product offering

Product offering

Core offering

HollandPTC is an independent outpatient proton therapy center that delivers precise radiation treatment to cancer patients using accelerated proton beams, exploiting the Bragg peak to concentrate dose in tumors while sparing surrounding healthy tissue. In addition to clinical care, the center conducts scientific research in biology, physics and technology, and clinical studies, and runs education programs for radiation oncologists, medical physicists, and radiotherapy technologists.

Product overview

HollandPTC (Holland Protonen Therapie Centrum) is a specialized proton therapy center founded by Erasmus MC, LUMC, and TU Delft. The organization operates three core functions: patient care (Protonentherapie), scientific research (Wetenschappelijk Onderzoek), and education (Onderwijs). Patient care includes precise proton radiation treatment for various cancers using three treatment rooms named Luit, Citer, and Parel. The research program covers five themes: Clinical Studies, High-Precision Proton Therapy, Health Economics, Flash Proton Therapy, and Combined Treatment Research. HollandPTC also operates a specialized Eye Treatment Line for ocular melanoma, the only such center in the Netherlands. The organization develops custom in-house software and hardware for treatment planning and delivery, though these are internal tools rather than commercial products.

Differentiator

Problem solved

Functional benefit

Products and services

  • Proton Therapy (Protonentherapie) Precise radiation therapy using accelerated protons instead of photons to treat cancer, enabling targeted tumor irradiation with reduced damage to surrounding healthy tissue and lower side effects. Provided to cancer patients referred by Dutch radiotherapist-oncologists.
  • Patient Care (Patiëntenzorg) Comprehensive patient care service including treatment planning, radiation delivery, and follow-up monitoring for proton therapy patients treated at HollandPTC.
  • Scientific Research (Wetenschappelijk Onderzoek) Cross-disciplinary research program focused on enhancing the added value of proton therapy through biology, physics & technology, and clinical studies. Includes research projects, researcher teams, and publication output.
  • Education and Knowledge Sharing (Onderwijs en Kennisdeling) Educational programs and knowledge sharing for radiation oncologists, clinical physicists, radiotherapy technologists, and technical personnel. Includes Boerhaave Nascholing e-learning and access to clinical and pre-clinical facilities.
  • HollandPTC Eye Treatment Line (Ooglijn) for Ocular Melanoma Specialized proton therapy treatment line for ocular melanoma using advanced techniques including clipless MR-eye guided planning, delivered in the dedicated De Parel treatment room. Provided to ocular melanoma patients in the Netherlands.
  • Plan Comparison (Planvergelijking) Clinical service comparing photon radiation treatment plans with proton therapy plans for individual patients with model-based indications to determine whether proton therapy offers better outcomes with fewer side effects, including ΔNTCP-based eligibility assessment.
  • Clinical Studies at HollandPTC Clinical research evaluating accepted and new clinical indications and testing new treatment strategies including hypofractionation, adaptive proton therapy, and combination therapy.
  • High-Precision Proton Therapy Research Research program focused on enhancing proton therapy through development and implementation of new technology and methodologies including advanced pre-treatment imaging, online adaptation, motion mitigation, AI use, and automated and probabilistic treatment planning.
  • Health Economics Research Research program assessing the health-economic benefits of proton therapy to determine its value, cost-effectiveness, and identify opportunities to maximize effectiveness and efficiency, led through collaboration with Erasmus University Rotterdam.
  • FLASH Proton Therapy Research Research program dedicated to understanding, developing, and clinically testing ultra-high dose rate proton therapy (≥40 Gy/s) with specific focus on the FLASH effect.
  • Combined Treatment Research Research program investigating proton therapy interaction with other treatments such as immunotherapy, hyperthermia, and targeted drugs to maximize treatment effectiveness in clinical practice.

Quantifiable outcome

  • Health insurers reimburse treatment for standard indications automatically
  • +3 more outcomes

Companies that use HollandPTC

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles5 records

HollandPTC technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

HollandPTC partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

  • Erasmus MCcoreStrategic or Co-development Partner · 1 January 2018Founding partner and major clinical collaborator. Erasmus MC radiotherapist-oncologists supervise treatments and conduct joint research. Prof. dr. Mischa Hoogeman serves as Principal Investigator. The partnership provides clinical expertise in radiotherapy and oncology, with joint research programs in proton therapy optimization and clinical outcomes.
  • LUMC (Leiden University Medical Center)coreStrategic or Co-development Partner · 1 January 2018Founding partner and clinical collaborator. LUMC radiotherapist-oncologists including Prof. dr. Coen Rasch supervise treatments. LUMC handles most ocular melanoma cases in the Netherlands (over 90%) and refers appropriate patients for proton therapy. Joint research in proton therapy for chordomas, vestibular schwannomas, and ocular melanoma.
  • TU DelftcoreStrategic or Co-development Partner · 1 January 2018Founding partner providing technical/physics expertise. TU Delft hosts HollandPTC on its campus. Joint research in proton therapy physics, imaging technology, treatment planning optimization, and AI applications. Prof. dr. Roland Kanaar and Prof. dr. Mischa Hoogeman (also Erasmus MC) lead research programs.
  • Varian Medical SystemsmajorTechnology or IntegrationEquipment and technology partner providing proton therapy systems and treatment planning software. Multiple joint research projects funded including Proton-DDR (2019), vestibular schwannoma research (2018), real-time dosimetry (2020), and FLASH therapy development (2020). Also provides access for commercial users to HollandPTC facilities.
  • Siemens HealthineersmajorTechnology or IntegrationMedical imaging technology partner providing CT and other imaging systems used in treatment planning and image guidance for proton therapy.
  • PhilipsmajorTechnology or IntegrationMedical technology partner providing imaging and healthcare technology solutions supporting treatment planning and patient care operations.
  • RaySearch LaboratoriesmajorTechnology or IntegrationTreatment planning software partner. Joint research project 'Probabilistic optimization and planning' funded by RaySearch Laboratories developing methods for probabilistic optimization in proton therapy treatment planning.
  • European Proton Therapy Network (EPTN)majorStrategic or Co-development PartnerEuropean network of proton therapy centers collaborating on best practices, guidelines, and harmonization of proton therapy treatment planning and delivery across Europe.
  • Medical DeltamajorStrategic or Co-development PartnerNetwork of life sciences, health and technology partners in the Delft-Leiden-Rotterdam region. Supports Health Technology Assessment (HTA) research and cross-institutional collaboration. Prof. dr. Coen Rasch holds Medical Delta professorship linking LUMC and TU Delft.
  • InHollandminorStrategic or Co-development PartnerApplied sciences university collaborating on radiation therapy technologist (RTT) training and education. Joint project 'Towards a sustainable RTT network' funded by European Union Erasmus+ program (2023) to harmonize proton therapy planning and delivery practices across Europe.
  • National DUPROTON research networkminorStrategic or Co-development PartnerDutch national research network for proton therapy collaboration among proton therapy centers in the Netherlands.
  • Erasmus University Rotterdam (EUR)majorStrategic or Co-development PartnerCollaboration through Erasmus School of Health Policy and Management on health economics research. Dr. Hedwig Blommestein leads HTA value proposition research. PhD students from EUR conduct cost-effectiveness and health technology assessment studies.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

HollandPTC competitors and assessment

Company assessment

Others

  • RaySearch Laboratories: Treatment planning software vendor and HollandPTC R&D partner. Comparable as the technology ecosystem participant whose RayStation platform is used in HollandPTC's plan-comparison workflow and whose probabilistic optimization research directly shapes the center's clinical capability.

Broad incumbents

  • IBA (Ion Beam Applications): Global leader in proton therapy equipment manufacturing and a broad incumbent in particle therapy. Comparable as the dominant infrastructure provider in the same clinical modality that HollandPTC operates, including competing ProteusONE/ProteusPLUS systems installed at peer centers worldwide.
  • Varian Medical Systems (a Siemens Healthineers company): HollandPTC's primary equipment and treatment-planning partner (ProBeam proton system). Comparable as the major radiotherapy incumbent whose installed base of photon and proton systems at other centers competes for the same oncology referral base and whose technology roadmap directly affects HollandPTC's clinical capabilities.
  • Hitachi (Hitachi High-Tech) Particle Therapy: Global proton therapy system manufacturer and operator (formerly Mitsubishi Electric). Comparable as a broad incumbent providing competing synchrotron-based proton systems installed at multiple academic medical centers, including European sites that compete for the same European patient and research demand.

Regional players

  • The Christie NHS Foundation Trust (Proton Beam Therapy Centre): UK NHS proton therapy center in Manchester treating pediatric and adult cases. Comparable as a publicly funded, hospital-integrated proton therapy center operating a similar clinical-research-education model, but in a different national reimbursement system (NHS) than HollandPTC's Dutch insurer model.

Direct peers

  • UMCG Protonentherapiecentrum: Proton therapy center at the University Medical Center Groningen, the other major Dutch proton facility. Directly comparable: same country, same WBMV-regulated indication framework, treats pediatric patients that HollandPTC does not, and competes for the same Dutch patient pool and referring physicians.
  • Maastro Proton Therapy: Proton therapy center at Maastro Clinic in Maastricht, the third Dutch proton facility. Directly comparable as a domestic competitor operating under the same WBMV license framework, treating overlapping model-based indications, and serving the same national referral network.

Emerging players

  • Provision CARES Proton Therapy Center (Nashville): US proton therapy center using Mevion compact systems. Comparable as a smaller-scale, single- or multi-room proton therapy operator with similar capital intensity and capacity dynamics, though operating under a US payer mix rather than Dutch mandatory insurance.
  • Mevion Medical Systems: Compact single-room proton therapy system manufacturer targeting smaller hospitals. Comparable as an emerging alternative technology platform whose success in reducing proton therapy capex could shift the competitive landscape for small-scale centers like HollandPTC.
  • Paul Scherrer Institute (PSI) – Center for Proton Therapy: Swiss research-and-treatment proton therapy center, historically the pioneer of pencil-beam scanning. Comparable as a research-driven proton therapy operation combining patient care with technology development (Gantry 2, Gantry 3) in a similar combined clinical-research model to HollandPTC.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

HollandPTC social profiles

Digital presence

HollandPTC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HollandPTC leadership team

Management profile

Number of profiles

Profiles1 record

HollandPTC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HollandPTC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HollandPTC

What does HollandPTC do?

HollandPTC is an independent outpatient proton therapy center that delivers precise radiation treatment to cancer patients using accelerated proton beams, exploiting the Bragg peak to concentrate dose in tumors while sparing surrounding healthy tissue. In addition to clinical care, the center conducts scientific research in biology, physics and technology, and clinical studies, and runs education programs for radiation oncologists, medical physicists, and radiotherapy technologists.

Is HollandPTC a public or private company?

HollandPTC is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was HollandPTC founded?

HollandPTC was founded in 2018. It employs 101 to 250 people.

Where is HollandPTC based?

HollandPTC is headquartered in Delft, Netherlands, in the Europe region.

How does HollandPTC make money?

One revenue line is on record: proton therapy treatment services.

Who are HollandPTC's main competitors?

RaySearch Laboratories is listed as an others. Broad incumbents are IBA (Ion Beam Applications), Varian Medical Systems (a Siemens Healthineers company) and Hitachi (Hitachi High-Tech) Particle Therapy. The Christie NHS Foundation Trust (Proton Beam Therapy Centre) is listed as a regional player. Direct peers are UMCG Protonentherapiecentrum and Maastro Proton Therapy. Emerging players are Provision CARES Proton Therapy Center (Nashville), Mevion Medical Systems and Paul Scherrer Institute (PSI) – Center for Proton Therapy.

Does HollandPTC have an API?

No public API is recorded for HollandPTC.

What industry is HollandPTC in?

HollandPTC's product category is Proton Therapy / Radiation Oncology. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology, with a secondary code of HLAIAGAI, Nuclear Medicine Clinical Services & Therapy Centers. Its NAICS code is 621512 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals